VITAPO is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 28 September 2015, 1 establishment.

What is the address of VITAPO?

The registered office of VITAPO is located at Kerkstraat 18, 2290 Vorselaar.

Is VITAPO still active?

Yes. According to the CBE (30 October 2026) VITAPO is active, legal situation “Normale toestand”, started on 28 September 2015.

Is VITAPO registered on Peppol?

Yes, VITAPO is registered on the Peppol network with ID 0208:0638890597.

What is the enterprise number of VITAPO?

The enterprise number of VITAPO is BE0638890597.

When was VITAPO founded?

VITAPO was founded on 28 September 2015.

Who are the directors of VITAPO?

According to the 2025 annual accounts, the directors of VITAPO are: MJ Pharma BV.

Is VITAPO a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 September 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did VITAPO make in 2025?

VITAPO posted a profit after taxes of € 104,047 in financial year 2025.

What is the revenue of VITAPO?

As a small company, VITAPO is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 112,510.

VITAPO (Private Limited) - Vorselaar - BE0638890597

Dossier VITAPO, printed on 30 October 2026 from databakkes.be/en/0638890597/vitapo. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

VITAPO from Vorselaar, company number BE0638890597, closed financial year 2025 with a result of € 104,047 after tax. For that financial year VITAPO recorded a gross margin of € 112,510 and equity of € 763,219. Compared with financial year 2024, the result moved from € 119,687 to € 104,047. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.

What it is worth Growing

€ 763,219

▲ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 104,047

▼ 13% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 13,119

▲ 127% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 25,291 paid out

24 % of the profit went to the shareholders, mostly to MJ Pharma (50 % of the shares). That is where the money ends up.

People and assets in 2025

Vehicles and equipment

€ 702

▼ 58% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 430,080

▼ 12% vs 2024

€ 62,221 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 1,211

▼ 81% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 9,947

▲ 227% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 103,450 Gross margin 2022: € 103,450 First fiscal year in the series	€ 102,536 Gross margin 2023: € 102,536 ▼ 1% vs 2022 (€ 103,450) Unfavourable step	€ 102,989 Gross margin 2024: € 102,989 Unchanged (€ 102,536) Favourable step	€ 112,510 Gross margin 2025: € 112,510 ▲ 9% vs 2024 (€ 102,989) Favourable step	▲ 9%
Profit after taxes	€ 64,516 Profit after taxes 2022: € 64,516 First fiscal year in the series	€ 114,153 Profit after taxes 2023: € 114,153 ▲ 77% vs 2022 (€ 64,516) Favourable step	€ 119,687 Profit after taxes 2024: € 119,687 ▲ 5% vs 2023 (€ 114,153) Favourable step	€ 104,047 Profit after taxes 2025: € 104,047 ▼ 13% vs 2024 (€ 119,687) Unfavourable step	▼ 13%
Equity	€ 565,624 Equity 2022: € 565,624 First fiscal year in the series	€ 564,777 Equity 2023: € 564,777 Unchanged (€ 565,624) Unfavourable step	€ 684,463 Equity 2024: € 684,463 ▲ 21% vs 2023 (€ 564,777) Favourable step	€ 763,219 Equity 2025: € 763,219 ▲ 12% vs 2024 (€ 684,463) Favourable step	▲ 12%
Total debts	€ 769,123 Total debts 2022: € 769,123 First fiscal year in the series	€ 773,202 Total debts 2023: € 773,202 ▲ 1% vs 2022 (€ 769,123) Unfavourable step	€ 622,930 Total debts 2024: € 622,930 ▼ 19% vs 2023 (€ 773,202) Favourable step	€ 530,224 Total debts 2025: € 530,224 ▼ 15% vs 2024 (€ 622,930) Favourable step	▼ 15%
Cash	€ 11,988 Cash 2022: € 11,988 First fiscal year in the series	€ 5,139 Cash 2023: € 5,139 ▼ 57% vs 2022 (€ 11,988) Unfavourable step	€ 5,767 Cash 2024: € 5,767 ▲ 12% vs 2023 (€ 5,139) Favourable step	€ 13,119 Cash 2025: € 13,119 ▲ 127% vs 2024 (€ 5,767) Favourable step	▲ 127%
Retained profit	€ 547,024 Retained profit 2022: € 547,024 First fiscal year in the series	€ 546,177 Retained profit 2023: € 546,177 Unchanged (€ 547,024) Unfavourable step	€ 665,863 Retained profit 2024: € 665,863 ▲ 22% vs 2023 (€ 546,177) Favourable step	€ 744,619 Retained profit 2025: € 744,619 ▲ 12% vs 2024 (€ 665,863) Favourable step	▲ 12%
Dividend	€ 115,000 Dividend 2022: € 115,000 First fiscal year in the series	€ 115,000 Dividend 2023: € 115,000 Unchanged (€ 115,000) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 115,000) Unchanged	€ 25,291 Dividend 2025: € 25,291 Unchanged (€ 0) Unchanged
Bank debt	€ 609,124 Bank debt 2022: € 609,124 First fiscal year in the series	€ 550,808 Bank debt 2023: € 550,808 ▼ 10% vs 2022 (€ 609,124) Favourable step	€ 491,238 Bank debt 2024: € 491,238 ▼ 11% vs 2023 (€ 550,808) Favourable step	€ 430,080 Bank debt 2025: € 430,080 ▼ 12% vs 2024 (€ 491,238) Favourable step	▼ 12%
Balance sheet total	€ 1,334,747 Balance sheet total 2022: € 1,334,747 First fiscal year in the series	€ 1,337,979 Balance sheet total 2023: € 1,337,979 Unchanged (€ 1,334,747) Unchanged	€ 1,307,393 Balance sheet total 2024: € 1,307,393 ▼ 2% vs 2023 (€ 1,337,979) Unchanged	€ 1,293,443 Balance sheet total 2025: € 1,293,443 ▼ 1% vs 2024 (€ 1,307,393) Unchanged	▼ 1%

Key figures of VITAPO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VITAPO?

What happened at VITAPO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 16, 2026 New annual accounts for financial year 2025: profit of € 104,047 (▼ 13% vs 2024). Source: NBB ↗
2020 MJ Pharma BV became a director. NBB
Sep 28, 2015 New establishment in Schilde. KBO
Sep 28, 2015 Start of the company according to the CBE. KBO

In short

From € 64,516 profit in 2022 to € 104,047 profit in 2025.

Paid € 90,352 in corporate taxes since 2022.

Best year ever: 2024, with € 119,687 profit.

Paid out € 255,291 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

MJ Pharma 50%

The stake of MJ Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

VITAPO

Apotheek Schyvens-Godin 100%

Behind VITAPO is MJ Pharma BV. The shares are held by MJ Pharma (50%). It owns 100% of Apotheek Schyvens-Godin itself.

Directors

According to the 2025 annual accounts

MJ Pharma BV

Bestuurder · represented by Julie Schyvens

Also active at: apotheek Schyvens

since 2020

Shareholders

MJ Pharma

50%

Participations

Apotheek Schyvens-Godin

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Kerkstraat 18

2290 Vorselaar

2.248.672.311

Fortsteenweg 7

2970 Schilde

Active since 28 September 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

apotheek Schyvens same network

€ 210,968 gross margin · 2025

MJ Pharma same network

€ 68,664 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0638.890.597

VAT number

BE 0638.890.597

Registered office

Kerkstraat 18, 2290 Vorselaar

Names & denominations

VITAPO

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 September 2015

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Activiteiten van holdings

Holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

VITAPO

Financials

What happened to VITAPO?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions